j-2

HSP27 inhibitor J2 (J2) (J2) is a HSP27 inhibitor, inhibits a production of HSP27 giant polymers, thereby having an effect of inhibiting a chaperone function of the HSP27 and reducing a cell protection function.

GSK-J2 is an inactive enantiomer of GSK-J1 that is lipophilic and serves as an inactive control for GSK-J21.

15-deoxy-Δ-12,14-Prostaglandin J2 is a PPARγ agonist.

15-Deoxy-Δ12,14-Prostaglandin J2-2-glyceryl ester is a derivative of 15-Deoxy-Δ-12,14-prostaglandin J2. The 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. This compound acts as a selective PPARγ (with an EC50 of 2 µM) and covalent PPARδ agonist. Additionally, 15-Deoxy-Δ-12,14-prostaglandin J2 effectively promotes the differentiation of C3H10T1/2 fibroblasts into adipocytes, with an EC50 of 7 μM.

Oxmetidine mesylate is an antagonist to Histamine H2 Receptors

Prostaglandin J2 (PGJ2), a derivative of Prostaglandin D2 (PGD2), serves as a potent agonist for PGD2 receptors (DP), exhibiting affinity constants (K i) of 0.9 nM and 6.6 nM for hDP and hCRTH2 receptors, respectively. It activates cyclic AMP production with an EC50 of 1.2 nM, induces oxidative stress, neuronal apoptosis, and promotes the accumulation of ubiquitinated (Ub) proteins. Notably, PGJ2's neurotoxic properties are implicated in the progression of neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD) [1] [2] [3] [4].

GSK-J2 sodium, the sodium form of GSK-J2, is an isomer of GSK-J1 and lacks specific activity. GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A [1].

Prostaglandin J2 (Standard) is a reference standard for research and analysis in studies involving Prostaglandin J2. Prostaglandin J2 (PGJ2), a derivative of Prostaglandin D2 (PGD2), serves as a potent agonist for PGD2 receptors (DP), exhibiting affinity constants (K i) of 0.9 nM and 6.6 nM for hDP and hCRTH2 receptors, respectively. It activates cyclic AMP production with an EC50 of 1.2 nM, induces oxidative stress, neuronal apoptosis, and promotes the accumulation of ubiquitinated (Ub) proteins. Notably, PGJ2's neurotoxic properties are implicated in the progression of neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD) [1] [2] [3] [4].

15-deoxy-Δ-12,14-Prostaglandin J2 (Standard) is a reference standard for research and analysis in studies involving 15-deoxy-Δ-12,14-Prostaglandin J2. 15-deoxy-Δ-12,14-Prostaglandin J2 is a PPARγ agonist.

13,14-Dihydro-15-keto prostaglandin J2 (13,14-Dihydro-15-keto-PGJ2) is the dehydrated product of 13,14-dihydro-15-keto PGD2.

15-deoxy-Δ12,14-Prostaglandin J2 Glutathione (15-Deoxy-Δ12,14-PGJ2 Glutathione) is a non-enzymatic adduct formed from the reaction of 15-deoxy-Δ12,14-PGJ2 with glutathione. The biological properties of this compound have not yet been determined.

15-Deoxy-Δ12,14-prostaglandin J2 serinol amide (15-Deoxy-Δ12,14-PGJ2 serinol amide) is a derivative of 15-deoxy-Δ12,14-PGJ2-2-glycerol ester.

JNJ-20788560 is a delta opioid receptor (DOR) agonist with analgesic activity. It is more selective for DOR than for mu opioid receptors (MOR).

JNJ-26489112 is a CNS-active agent and inhibitor of voltage-gated Na+ channels and N-type Ca2+ channels with broad-spectrum anticonvulsant activity in rodents and can be used to study neurological disorders.

The ED50 of J-2156 in rats for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws was 3.7 and 8.0 mg/kg, respectively. J-2156 is a high potent, selective somatostatin receptor type 4 (SST4 receptor) agonist with IC5

LJ-2698 is an adenosine A3 receptor antagonist under investigation for treating emphysema and DKD (Diabetic Kidney Disease). In mouse lung models, LJ-2698 effectively mitigates elastase-induced adverse effects and inhibits matrix metalloproteinase activity and apoptosis. Additionally, it is being explored for its potential in treating diabetic nephropathy, successfully preventing various types of kidney damage in mice.

JNJ-2901 is an inhibitor of M. tuberculosis cytochrome bc1:aa3. It effectively reduces bacterial load in acute and chronic mouse infection models of M. tuberculosis H37Rv-ΔcydAB. JNJ-2901 is useful for tuberculosis (TB) research.

DNJ-20 is an α-glucosidase inhibitor with an IC50 of 55.3 μg/mL. It exhibits broad-spectrum activity against SARS-CoV-2. By interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), DNJ-20 hinders the proper processing of viral glycoproteins, thus blocking the formation and infection of viral particles. It is effective against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43, with IC50 values reaching up to 1.49 μM. DNJ-20 can be utilized for pan-coronavirus research.

MJ-26 is an inhibitor targeting Menin, characterized by a high binding affinity (Ki: 0.56 μM) and significant antiproliferative activity. It functions by inhibiting Menin-MLL interaction and promoting the degradation of Menin protein. MJ-26 demonstrates notable antitumor effects against acute myeloid leukemia (AML) and is applicable for AML research.

JNJ-28312141 is an orally active CSF1R inhibitor and a FLT3 inhibitor. JNJ-28312141 is a new agent with potential therapeutic activity in acute myeloid leukemia and in settings where CSF-1-dependent macrophages and osteoclasts contribute to tumor growth a

JNJ-28330835 is a selective androgen receptor modulator with minimal prostate hypertrophic activity.

JNJ-28610244 is a specific agonist of the H4 receptor. It acts by blocking Mac-1-dependent activation of p38 MAPK.

ZYJ-25e is an oral histone deacetylase inhibitor (HDACi) with potent antitumor activities.

JNJ-2408068 is an inhibitor of respiratory syncytial virus (RSV). JNJ-2408068 exhibited potent antiviral activity with EC50 of 2.1 nM. A similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50= 0.9 nM). JNJ-2408068 interferes with